{"filing":{"accession_number":"0001213900-26-098219","cik":"0001949257","ticker":"RDPTF","company_name":"Radiopharm Theranostics Ltd","form":"6-K","filing_date":"2026-09-09","report_date":"2026-09-09","primary_document":"ea0304932-6k_radio.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1949257/000121390026098219/ea0304932-6k_radio.htm"},"events":[{"id":32201,"run_id":29582,"accession_number":"0001213900-26-098219","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"This is an announcement of positive Phase 1 clinical trial data for RAD301, a radiopharmaceutical candidate in development for pancreatic cancer. The disclosure reports favorable safety, biodistribution, and significant tumor uptake results that support advancement to Phase 2 development. While this is a material clinical milestone for a clinical-stage biopharmaceutical company, it does not fit the discrete event categories (not an earnings release, M\u0026A activity, executive change, or financial obligation). It is a material operational/strategic milestone—a positive clinical development outcome that would affect investor assessment of the company's pipeline progress and value.","company_name":"Radiopharm Theranostics Ltd","ticker":"RDPTF","filing_date":"2026-09-09","form":"6-K","submitted_at":null,"items":[{"id":35314,"accession_number":"0001213900-26-098219","item_number":"EX-99.1","item_title":"ea030493201ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This is an announcement of positive Phase 1 clinical trial data for RAD301, a radiopharmaceutical candidate in development for pancreatic cancer. The disclosure reports favorable safety, biodistribution, and significant tumor uptake results that support advancement to Phase 2 development. While this is a material clinical milestone for a clinical-stage biopharmaceutical company, it does not fit the discrete event categories (not an earnings release, M\u0026A activity, executive change, or financial obligation). It is a material operational/strategic milestone—a positive clinical development outcome that would affect investor assessment of the company's pipeline progress and value.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-09T12:01:05.471977+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":35314,"accession_number":"0001213900-26-098219","item_number":"EX-99.1","item_title":"ea030493201ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This is an announcement of positive Phase 1 clinical trial data for RAD301, a radiopharmaceutical candidate in development for pancreatic cancer. The disclosure reports favorable safety, biodistribution, and significant tumor uptake results that support advancement to Phase 2 development. While this is a material clinical milestone for a clinical-stage biopharmaceutical company, it does not fit the discrete event categories (not an earnings release, M\u0026A activity, executive change, or financial obligation). It is a material operational/strategic milestone—a positive clinical development outcome that would affect investor assessment of the company's pipeline progress and value.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-09T12:01:05.471977+00:00","company_name":"Radiopharm Theranostics Ltd","ticker":"RDPTF","filing_date":"2026-09-09"}]}